Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.
about
Multiple roles for nicotine in Parkinson's diseaseLevodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatmentStriatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?Functional neuroimaging in Parkinson's diseaseEndogenous opiates and behavior: 2006Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalingEffects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Nicotine and Parkinson's disease: implications for therapy.The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats.Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus.Synaptic protein alterations in Parkinson's disease.Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.Non-dopaminergic treatments for motor control in Parkinson's disease.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.Non-human primate models of PD to test novel therapies.Memantine and reduced time with dyskinesia in Parkinson's Disease.CNS penetration of the opioid glycopeptide MMP-2200: a microdialysis study.Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson’s disease
P2860
Q22252514-3427DD47-9CB8-4EEF-B886-5467E6E691D4Q24647141-4511991F-7B09-4341-92B0-7A05880B03B9Q26768220-CEFF5851-E2EF-4548-B61F-D42C24DD324DQ27013767-B4AB279F-ABF8-4691-80BC-BE362255E235Q28752585-B4A871AA-D765-4674-B6C9-345D36C7EA19Q33428476-AC60E860-B904-488B-8649-53C7CC7319F0Q35196411-3D6FDA00-3693-4EFD-9395-9E6FCC7EE98CQ35589979-308BF2C5-21E7-4D75-898E-80F7F27634C5Q35601652-82A3AC41-A40D-473F-9DA3-4342F0B0A04AQ37341623-A75E4FD1-B802-43EF-B262-C63F924FB247Q37390730-23459F45-480C-4F7C-9E29-4C5A669EEC5BQ37972089-B5C93CC0-2182-4C93-B4D6-AD0C00F28CF9Q38103966-B76219F8-49A8-416E-BBC3-6D5B9CD0E4B2Q38126817-A5BAF22B-9D03-42A8-9062-67540F5BE667Q38563981-FB210965-2E91-4779-93FE-81E8C654962DQ38636630-6D823608-3A86-4C03-BB04-2EC29E40AE66Q38684679-97BDD3C6-7F07-48FD-A3AD-EC9167111A19Q39229450-DBEBF724-A362-4B6B-B3ED-47CD9F92B580Q40669186-D8327710-DA56-4339-B848-368F5F62667DQ42573127-95DE70EB-8588-4D25-BDD0-BEC74DA34B02Q45985296-55C6A885-8166-4791-8FBF-BB10C26F9A09Q46280394-446F369D-B35E-4DDF-A49E-B8188F37D6DDQ46552807-AA795192-F6FB-4FAA-AA2B-D08652682EF2Q58870313-D176428A-A698-4D36-AD02-4B7EB557F618
P2860
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Translation of nondopaminergic ...... success and roads to failure.
@ast
Translation of nondopaminergic ...... success and roads to failure.
@en
type
label
Translation of nondopaminergic ...... success and roads to failure.
@ast
Translation of nondopaminergic ...... success and roads to failure.
@en
prefLabel
Translation of nondopaminergic ...... success and roads to failure.
@ast
Translation of nondopaminergic ...... success and roads to failure.
@en
P2860
P50
P356
P1433
P1476
Translation of nondopaminergic ...... success and roads to failure.
@en
P2860
P304
P356
10.1002/MDS.20936
P407
P577
2006-10-01T00:00:00Z